This study evaluated the prevalence of asthma patients who would become eligible for biologic therapies under broadened eligibility criteria, and the associated cost implications of expanding access to these treatments.
The paper text provided contains only metadata (title, DOI, journal, publication date) with no abstract or full-text content, making it impossible to extract specific results, methods, sample sizes, or detailed findings.
Explore related topics
